Search This Blog

Friday, May 3, 2019

Emergent BioSolutions (EBS) Misses Q1 EPS by 22c, Offers Guidance

Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($0.13), $0.22 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $190.6 million versus the consensus estimate of $201.16 million.
GUIDANCE:
Emergent BioSolutions sees Q2 2019 revenue of $200-220 million, versus the consensus of $254.14 million.
Emergent BioSolutions sees FY2019 revenue of $1.06-1.14 billion, versus the consensus of $1.08 billion.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)